MYH14 and ocular melanoma: The hope that OM will be able to benefit a selected population of high-risk HFrEF still awaits a deeper understanding of its pharmacological action at the clinical level, which will go hand in hand with the clarification of the many obscure points regarding the molecular mechanism of its action as a myosin modulator.